In our opinion, the use of inhibitors or immunotherapy for regulating CD39/CD73 axis could be a promising therapeutical approach by promoting the increase in the ATP and the decrease in the adenosine levels, causing strong immune and anti-tumor responses. The gene discussed is ENTPD1; the disease is neoplasm.